Wednesday - December 03, 2025

Drone Surveying Set to Grow from $1.97B to $11.49B by 2035 as ZenaTech, Inc. (NASDAQ: ZENA) Expands Its U.S. Footprint

The drone surveying market is expected to continue to gain momentum due to increasing demand for aerial intelligence and high-precision mapping across major sectors such as agriculture, mining, construction, and environmental monitoring. Fact.MR analysis indicates that the industry will be … Continue reading

Crohn’s Disease Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s, “Crohn’s Disease Pipeline Insight 2025” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the Crohn’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading

Spinal Cord Injury Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Spinal Cord Injury Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Spinal Cord Injury pipeline landscape. It covers the Spinal Cord Injury pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading

Triple Negative Breast Cancer Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Triple Negative Breast Cancer Pipeline Insight 2025” report provides comprehensive insights about 165+ companies and 170+ pipeline drugs in the Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer Pipeline drug profiles, including clinical and … Continue reading

Stargardt Disease Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Stargardt Disease Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Stargardt Disease pipeline landscape. It covers the Stargardt Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading

Obesity Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Obesity Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment … Continue reading

Glucagon-Like Peptide Agonist Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Glucagon-Like Peptide Agonist Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in the Glucagon-Like Peptide Agonist pipeline landscape. It covers the Glucagon-Like Peptide Agonist Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading

Mantle Cell Lymphoma Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s, “Mantle Cell Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Mantle Cell Lymphoma pipeline landscape. It covers the Mantle Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading

Ulcerative Colitis Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Ulcerative Colitis Pipeline Insight 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading